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H I V
Antigen-specific antibody Fc glycosylation enhances 
humoral immunity via the recruitment of complement
Giuseppe Lofano1*, Matthew J. Gorman1*, Ashraf S. Yousif1,2*, Wen-Han Yu1,3*, Julie M. Fox4, 
Anne-Sophie Dugast1, Margaret E. Ackerman5, Todd J. Suscovich1, Joshua Weiner5,  
Dan Barouch1,6, Hendrik Streeck7, Susan Little8, Davey Smith8,9, Douglas Richman8,9,  
Douglas Lauffenburger3, Bruce D. Walker1,10,11, Michael S. Diamond4, Galit Alter1†
HIV-specific broadly neutralizing antibodies (bNAbs) confer protection after passive immunization, but the immu-
nological mechanisms that drive their development are poorly understood. Structural features of bNAbs indicate 
that they originate from extensive germinal center (GC) selection, which relies on persistent GC activity. However, 
why a fraction of infected individuals are able to successfully drive more effective affinity maturation is unclear. 
Delivery of antigens in the form of antibody-immune complexes (ICs), which bind to complement receptors (CRs) 
or Fc receptors (FcRs) on follicular dendritic cells, represents an effective mechanism for antigen delivery to the 
GC. We sought to define whether IC-FcR or CR interactions differ among individuals who develop bNAb responses 
to HIV. Enhanced Fc effector functions and FcR/CR interactions, via altered Fc glycosylation profiles, were observed 
among individuals with neutralizing antibody responses to HIV compared with those without neutralizing anti-
body activity. Moreover, both polyclonal neutralizer ICs and monoclonal IC mimics of neutralizer antibodies in-
duced higher antibody titers, higher-avidity antibodies, and expanded GC B cell reactions after immunization of 
mice via accelerated antigen deposition within B cell follicles in a complement-dependent manner. Thus, these 
data point to a direct role for altered Fc profile/complement interactions in shaping the maturation of the humoral 
immune response, providing insights into how GC activity may be enhanced to drive affinity maturation in next- 
generation vaccine approaches.
INTRODUCTION
The development of a protective vaccine against HIV will likely re-
quire the induction of highly cross-reactive broadly neutralizing anti-
bodies (bNAbs). Although current vaccination regimens can readily 
induce Abs capable of neutralizing autologous viruses (1, 2), these im-
munization strategies have generated only weakly cross-neutralizing 
(heterologous) Abs (3, 4). Although vaccination has failed to induce 
Abs with appreciable neutralization breadth, 5 to 30% of infected 
individuals naturally develop bNAbs, albeit after several years of in-
fection (5, 6) and one step behind the autologous virus (7). Thus, elu-
cidating the immunological processes that allow some individuals to 
overcome the immunologic barrier to developing neutralizing breadth 
may provide critical insights for the development of a vaccine capable 
of inducing bNAbs.
Although our understanding of the molecular and structural 
features of Abs that allow for broad neutralization has increased 
markedly over the past decade (8, 9), the underlying immunological 
pathways that lead to these unusual features have yet to be fully elu-
cidated. Nearly all bNAbs develop after extensive somatic hyper-
mutation and often contain mutated framework regions (9, 10), 
features that are indicative of the prolonged affinity maturation. 
Previous studies have linked high viral loads, low CD4 T cell counts, 
and immune activation in the evolution of bNAbs (11–14). In the 
setting of low levels of viremia and high CD4 counts, bNAb activity 
still evolves, but only in the setting of a unique plasma type I inter-
feron and germinal center (GC)–centric cytokine signature, pointing 
to the need for persistent GC activity (15). Yet, how these individ-
uals maintain GC activity, particularly in the setting of low antigenic 
loads, is unclear.
Antigen delivery to the lymph node, and specifically to follicular 
dendritic cells (FDCs), plays a key role in both initiating and sus-
taining the GC reaction (16). Specifically, antigen may be delivered to 
the lymph node via both “naked” antigen diffusion from the lymph 
or active antigen delivery via the delivery of antigen in the form of 
immune complexes (ICs) by noncognate B cells or local macrophages 
(17–20). Although HIV antigens likely arrive in the GC in the ab-
sence of Ab opsonization in acute HIV infection, high titers of HIV- 
specific Abs are induced over the course of infection that contribute to 
IC formation (21, 22), antigen capture and delivery, and seeding of 
antigens in the GC (23). However, whether differences in IC quality 
could contribute to GC generation and persistence, affinity maturation, 
and the evolution of neutralization breadth is unknown.
IC activity is modulated by both the Fab and Fc domains of the 
Ab. The Fab drives antigen specificity, whereas the Fc region deter-
mines which innate immune receptors, including Fc receptors (FcRs) 
and complement receptors (CRs), ICs can bind. Depending on the 
FcRs and CRs engaged by an IC, antigens can be rapidly destroyed 
or transported to the GC for antigen presentation (18, 19, 24–27). 
Hence, modifications to the Fc domain, including changes in Ab 
isotype/subclass and glycosylation (28–31), may have a profound im-
pact on IC delivery via improved IC affinity for particular FcRs/CRs. 
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Along these lines, influenza-specific Fc Ab glycosylation after vacci-
nation is associated with enhanced affinity maturation of the influenza- 
specific response (32), highlighting the potential influence of the 
Fc domain changes after vaccination on the antiviral activity of the 
vaccine-induced immune response.
We speculated that qualitative changes in the Fc domain track with 
the development of bNAbs during HIV infection and point to the 
mechanism by which the Fc domain of the Ab may be leveraged to 
drive the evolution of highly affinity-matured bNab responses. Using 
“systems serology” (33), we observed significant differences in the 
Fc profiles of HIV-specific Abs in individuals who developed neu-
tralizing breadth (neutralizers) compared with those who did not 
(non-neutralizers). Moreover, immunization with ICs generated with 
polyclonal Abs from neutralizers induced higher HIV-specific Ab re-
sponses after vaccination. This biological activity was linked to particu-
lar Ab glycosylation profiles, which, when replicated with monoclonal 
IC immunization, resulted in enhanced IC capture by noncognate B cells, 
accelerated IC deposition within B cell follicles, and elevated Ab titers 
and avidity Ab production in a complement-dependent manner. Col-
lectively, these data point to Fc glycosylation as a direct modulator of 
B cell immunity and suggest an approach by which next-generation 
vaccines can exploit both ends of the Ab to drive enhanced B cell af-
finity maturation that may be required against highly mutable targets.
RESULTS
Selective Fc functional profile differences  
exist among neutralizers
Given previous associations of the evolution of neutralizing Ab 
breadth in the setting of high immune activation, low CD4 counts, and 
high viral loads (12, 14), we aimed to dissect the potential involve-
ment of changes in IC biology in a group of spontaneous controllers 
of HIV (≤2000 copies/ml), a fraction of whom developed bNAb re-
sponses, despite the absence of high levels of plasma antigenemia (15). 
Despite lower viremia, previous studies demonstrated that equal num-
bers of controllers evolve neutralization breadth (15) compared with 
normal progressors (12, 14). Seventy-one participants were included 
in this study, with neutralization breadth ranging from 9 to 100% 
coverage of a panel of 11 tier 2/3 viruses (neutralizers) that were com-
pared with a matched group of 60 participants with no evidence of 
neutralizing Ab breadth (0% neutralizing activity across 11 tier 2 and 
tier 3 viruses; non-neutralizers). The two groups were matched for 
duration of infection, viral loads, and CD4 counts.
No differences in the ability of Abs to recruit natural killer (NK) 
cells to kill HIV envelope–coated target cells in an Ab-dependent 
cellular cytotoxicity (ADCC) assay were observed between the neu-
tralizers and non-neutralizers (Fig. 1A). In contrast, significant dif-
ferences were observed in the capacity of neutralizer Abs to direct 
Ab-dependent cellular phagocytosis (ADCP) and Ab-dependent 
complement deposition (ADCD) (Fig. 1, B and C). Given the use of 
different FcRs in driving distinct innate functions, these data sug-
gested that neutralizer Abs were selectively skewed to drive enhanced 
phagocytic and complement-depositing activity, but not NK cell 
cytotoxicity.
To further dissect the specific FcRs that were selectively recruited 
by neutralizer Abs, we used a multiparametric Luminex assay to 
measure differences in IC binding to a spectrum of Fc receptors 
(FcRs) and complement proteins. With a panel of HIV envelope–
conjugated Luminex beads, ICs were formed, and binding to the ICs 
by FcRs and complement was measured. A subset of the original 
cohort, composed of 38 individuals broadly covering a range of neu-
tralization breadths (0 to 100%) (Fig. 2A and table S1), for whom 
sufficient plasma was available, was included in this analysis. The 
individuals included 26 participants who neutralized between 9 and 
100% of the 11 tested tier 2/3 viruses and 12 participants with no evi-
dence of neutralizing Ab breadth (Fig. 2A and table S1). In addition, 
viral loads, CD4 counts, days after diagnosis, and distribution of 
ADCD, ADCC, and ADCP responses were similar between the 
groups. Marked differences were observed among the neutralizer 
and non-neutralizer Abs in their ability to bind to C1q and FcRs 
(Fig. 2B). Specifically, a higher proportion of neutralizers exhibited 
enhanced gp41-specific FcR binding and enhanced gp120 and gp140 
binding to FcRIIIA and FcRIIIB, and a select set of neutralizers 
also showed stronger binding to C1q (Fig. 2B). Univariate analysis 
highlighted the overall elevated levels of FcR/C1q binding Abs among 
neutralizers (Fig. 2C). Moreover, positive associations between breadth 
and FcR/C1q binding were observed across all HIV-specific Ab re-
sponses; however, only gp140- and gp41-specific Ab binding to FcRIIB 
and C1q was statistically significant (Fig. 2D). These data suggest an 
overall enhanced FcRs and C1q binding profile in Abs from neu-
tralizers compared with non-neutralizers, consistent with enhanced 
ADCD and ADCP (Fig. 1). Furthermore, previous longitudinal analy-
sis pointed to significantly enhanced Fc function and receptor binding 
among individuals who went on to generate neutralizing responses 
before the evolution of the neutralizing Abs (34). Likewise, analysis 
of plasma samples from a separate cohort of acutely infected indi-
viduals, half of whom went on to generate neutralizing Abs, pointed 
to selectively elevated gp120-specific FcRIIA binding preceding the 
evolution of bNAbs after 2 years of infection (Fig. 2E) (7). Given the 
importance of both FcR and C1q in the delivery of IC cargo to the GC 
(17, 35, 36), these data point to unique IC profiles among neutralizers 
with a higher intrinsic capacity to interact with Fc-binding proteins 
involved in antigen delivery to the GC, thereby potentially contribut-
ing to persistent GC activity and enhanced affinity maturation.
HIV-specific Abs from neutralizers promote GC reactions
To test the hypothesis that differences in Fc profiles generated in 





















































Fig. 1. Unique Fc functional profiling of HIV-specific Abs from neutralizers. 
(A to C) Serum Abs from neutralizers (N; purple) and non-neutralizers (NN; yellow) were 
evaluated for their ability to promote NK-dependent ADCC against gp120-pulsed 
CD4+ T cells (A), monocyte-directed phagocytosis of gp120-functionalized fluorescent 
beads (B), or complement deposition (C3b) on the surface of gp120-pulsed CD4+ 
target cells (C). All assays were performed in duplicate or triplicate across all 131 in-
dividuals. An unpaired t test was used for statistical analysis. *P < 0.05 and **P < 0.01. 
The horizontal bars in all panels indicate mean.
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GC reactions and affinity maturation, we generated ICs from neu-
tralizers and non-neutralizers. Ab pools were generated from four 
neutralizers and four non-neutralizers, matched for gp120-specific 
Ab titers and avidity (fig. S1A). Specifically, recombinant HIV gp120 
proteins were complexed with polyclonal Abs from neutralizer and non- 
neutralizer pools at Ab concentrations aimed at achieving equivalent 
IC occupancy (fig. S1, B and C). All complexes were co-delivered to 
mice with alum as a baseline comparator to standard immunization. 
Thus, equivalent amounts of alum-adjuvanted ICs, alum-adjuvanted 
gp120, or alum alone were administered. Mice received two immu-
nizations, 3 weeks apart, and 10 days after the last immunization, 
gp120-specific Ab serum titers, high-avidity gp120-specific Ab titers, 
and the frequency of GC B cells in the draining lymph nodes of immu-
nized mice were measured. As expected, higher levels of gp120-specific 
Abs were induced in IC-immunized mice compared with mice vacci-
nated with antigen alone (Fig. 3A). Mice immunized with the ICs 
from neutralizers demonstrated slightly higher levels of overall Ab 
titers and more avid Abs compared with the mice vaccinated with 
ICs from non-neutralizers (P < 0.05; Fig. 3, A and B). Furthermore, 
higher frequencies of GC (CD19+CD30−CD95+) B cells were observed 
after immunization with ICs from neutralizers compared with mice 
immunized with ICs from non-neutralizers (Fig. 3C). Given the over-
lap in mouse and human FcR responses to human monoclonal Abs 
(mAbs) (37), suggesting sufficient cross-species interaction, these data 
suggest that the Fc differences in neutralizer Abs may not only rep-
resent a biomarker of a more effective humoral immune response 
but also contribute to differences in GC activity.
Unique antigen-specific Ab glycosylation and elevated 
immunoglobulin G1 are enriched among neutralizers
To define the biophysical differences in neutralizer and non- 
neutralizer IC profiles that may have contributed to enhanced 
C


























































































































































































































































Fig. 2. Enhanced, but selective, FcR and complement binding by HIV-specific Abs in neutralizers. (A) The rainbow heat map shows the breadth of neutralization and 
sample ID number across the 26 neutralizers and 12 non-neutralizers that were profiled more deeply in this and subsequent figures. (B) The larger heat map illustrates 
the binding capacity (MFI) of gp140-, gp120-, gp41-, and p24-specific serum Abs to FcRIIA, FcRIIB, FcRIIIA, FcRIIIB, and C1q protein. Row 19 represents the breadth of 
neutralization. Each additional row represents the binding level for a single antigen specificity to a single FcR/C1q. Each column represents one individual (sample ID 
number is below the heat map), either a neutralizer (red box) or a non-neutralizer (blue box). Data were normalized across rows. The scale bar represents the Z-normalized 
scores. (C) The dot plot represents the representative univariate binding of gp120-specific Abs from each group to FcRIIA, FcRIIB, FcRIIIA, FcRIIIB, and C1q. (D) The heat 
map strip highlights the correlation between gp140-, gp120-, gp41-, and p24-specific Ab binding to each FcR/C1q and the breadth of neutralization across all neutralizers and 
non-neutralizers. (E) The hybrid dot/bar plot shows the evolution of gp120-specific FcRIIA binding Abs in the first year after infection in a group of acutely infected HIV 
participants, half of which went on to develop bNAbs (purple) or not (yellow). Each dot represents one individual, with neutralizers (N) in violet and non-neutralizers (NN) in 
yellow. A Mann-Whitney test was used for statistical analysis to compare groups in (C). An ANOVA, with a post hoc Tukey’s test, was used to compare between groups across 
time points in (E). A Spearman correlation with a post hoc Bonferroni correction was used to examine the relationship between Fc profiles and breadth of neutralization 
(D). *P < 0.05 and **P < 0.01. The horizontal bars in all panels indicate mean. Error bars represent standard error of mean (SEM) in (C) and standard deviation (SD) in (E).
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humoral immune responses, we interrogated differences in both im-
munoglobulin G (IgG) subclass selection levels and Fc glycosylation 
profiles on HIV-specific Abs by capillary electrophoresis. Although 
no differences were observed in antigen-specific IgG2, IgG3, and IgG4 
levels across the two groups, neutralizers had higher HIV-specific 
IgG1 titers to all HIV antigens, but not to influenza hemagglutinin (HA) 
(Fig. 4, A and B, and fig. S2A), highlighting the infection-specific 
change in Ab levels. Elevated HIV-specific IgG responses were not 
linked directly to viral load, days after diagnosis, or viremic or elite con-
troller status, but did negatively correlate with CD4 count (fig. S3, A 
to D) (14, 37, 38). However, as previously reported, a trend was 
observed in neutralization breadth and CD4 counts and viral load 
(fig. S3, E and F) (12, 14, 38). Thus, differences in IC activity may be 
attributable to higher overall HIV-specific IgG1 levels, which could 
account for improved overall FcR binding. However, selectively 
enhanced binding to C1q and FcRII (Fig. 2C) and immunization 
differences using matched Ab-bound complexes (Fig. 3) could 
not be explained by elevated IgG1 levels or differential subclass 
selection profiles.
Given the emerging appreciation for the role of antigen-specific Ab 
glycoforms in shaping Fc activity (28, 29), we profiled HIV-specific 
Ab glycosylation (39). Using standard capillary electrophoresis (39) 
on equivalent amounts of enzymatically collected Fc glycans from 
neutralizers and non-neutralizers, we observed elevated levels of 
sialylated glycan structures on HIV envelope–specific IgG-Fcs from neu-
tralizers compared with non-neutralizers. In contrast, non-neutralizers 
had higher levels of singly galactosylated (G1) structures on their 
HIV-specific IgG1 Abs (Fig. 4, C and D). Thus, selective differences 
in sialylation and galactosylation were observed among neutralizers 
and non-neutralizers, pointing to qualitative differences in IgG1 Ab 
after translational modifications.
To further define the minimal HIV-specific features that were 
selectively enriched among neutralizers, we used an orthogonal multi-
variate partial least square discriminant analysis PLS-DA combining 
all gp120-specific features. Using all Fc profile features, we observed 
nearly complete separation between neutralizers and non-neutralizers 
(Fig. 4E). The dominant features that selectively split the two groups 
included the level of sialylated glycan structures and overall levels of 
gp120-specific IgG1 Abs, with the percentage of sialylated gp120- 
specific Abs ranking as the top distinguishing feature (Fig. 4, E and F). 
Consistent with previous studies pointing to an association between 
the levels of vaccine-induced sialylated Abs and Ab affinity matura-
tion (32), sialylated HIV-specific Abs were selectively enriched among 
neutralizers, pointing to a potential link between posttranslational 
Ab sialylation and affinity maturation across disease and vaccination. 
However, whether sialylation represents a biomarker of a more highly 
affinity-matured immune response or directly contributes to affinity 
maturation remains unknown.
HIV Ab glycoforms modulate IC-driven innate  
and adaptive immunity
To define the involvement of sialylated Abs in driving affinity matu-
ration and to separate the role of sialylation from Ab titer differences 
between neutralizers and non-neutralizers (fig. S1A), we immunized 
animals with ICs generated with a single mAb, but with differential 
glycosylation. ICs were generated with an HIV-specific mAb (PGT121) 
that was fractionated and enzymatically prepared into three sepa-
rate Ab Fc fractions to generate agalactosylated ICs (G0-ICs), non-
sialylated galactosylated ICs (G1/G2 NS-ICs), or sialylated ICs (G1/G2 
S-ICs). Despite the presence of a glycan in the PGT121 Fab (40), 
removal of sialylation did not affect PGT121 binding or affinity (fig. 
S4, A to D). Mice were immunized with alum-formulated ICs, alum- 
formulated antigen alone, or alum alone, and Ab levels, avidity, and 
B cell frequencies were interrogated 10 days after the second immu-
nization. Mice immunized with S-ICs exhibited increased gp120- 
specific IgG titers compared with those immunized with NS-ICs, 
G0-ICs, or gp120 alone (Fig. 5A). Moreover, immunization with 
S-ICs also induced more avid gp120-specific Abs compared with all 
other immunized groups (Fig. 5A). Although the Fab domain may 
also be sialylated (41), such as in PGT121 (40), only the Fc glycan 
contributes to FcR/complement interactions in an indirect manner 
by reshaping the Ab Fc to tune FcR/complement engagement (42). 
These data implicate Fc sialylation as a direct modulator of the 
humoral immune response, rather than a simple biomarker of an 
affinity-matured response.
Sialylated ICs drive enhanced antigen deposition
To begin to dissect the mechanism by which S-ICs contribute to en-
hanced B cell affinity maturation, we examined the distribution of 
these ICs early after immunization. A number of cells have been im-
plicated in IC capture and transfer to GCs, including sinusoidal macro-
phages (SSMs) and noncognate B cells that collectively transfer ICs 
to FDCs. Glycan-fractionated PGT121-ICs were prepared with a fluo-
rescently labeled gp120. The ICs were delivered intravenously, and 
IC capture was measured by flow cytometry and immunofluorescent 
microscopy 1 and 3 hours after IC administration. After 1 hour, sig-
nificantly higher frequencies of ICs were observed on B cells and FDCs 
in the presence of S-ICs compared with NS-ICs or antigen alone 
(Fig. 5B); after 3 hours, SSMs, B cells, and FDCs captured higher 
levels of ICs in the presence of sialylated Abs.
To visualize the localization of the ICs after delivery, we per-
formed fluorescence microscopy on splenic follicles. One hour after 
vaccination, follicles from mice receiving the sialylated ICs exhibited 
greater IC deposition within the follicle than those receiving the non-


































































Fig. 3. Neutralizer ICs drive higher-avidity Abs and expanded GC B cell re-
sponses. (A to C) BALB/c mice were immunized twice, 3 weeks apart, with alum- 
adjuvanted gp120 ICs (ICs-alum) generated with serum Abs from four neutralizers 
(N) or four non-neutralizers (NN) (n = 5 to 8 mice per group, two experiments). 
Control groups received alum-adjuvanted gp120 or adjuvant alone. Ten days after 
the last immunization, we measured the titers of gp120-specific IgG Abs (A), the 
titers of high-avidity gp120-specific IgG Abs (B) in sera, and the percentage of GC 
B cells (C), defined as live CD3−CD19+CD38−CD95+ cells, in draining lymph nodes of 
immune mice. All assays were run in duplicate, and a Mann-Whitney test was used to 
compare responses induced by neutralizer (N) or non-neutralizer (NN) immunized 
animals. *P < 0.05 and **P < 0.01. The horizontal bars in all panels indicate mean, 
and error bars in all panels represent SEM.
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FDCs, whereas NS-IC deposition, though infrequent, was observed 
closer to SSMs. Furthermore, vaccination with the sialylated ICs in-
duced higher numbers of gp120+ FDC areas per follicle, two on 
average, and of larger size of the areas, compared with vaccina-
tion with nonsialylated ICs (Fig. 5D). Furthermore, after 3 hours, 
greater antigen deposition was observed in the presence of S-ICs 
compared with NS-ICs, colocalizing with GL-7+ GC B cells (Fig. 5E). 
These data suggest that S-ICs may contribute to enhanced humoral 
immune activity via the rapid and effective deposition of ICs within 
GCs via enhanced IC capture and delivery to the follicle. How 
sialylated ICs are selectively captured and delivered to the follicle 
remains unknown.
Sialylated Fc antigen effects are complement-dependent
Emerging data suggest that complement has an essential role in 
IC-mediated antigen deposition on FDCs (17). We assessed whether 
uptake of sialylated ICs depended on complement. Using a noncognate 
reporter B cell line, Raji cells, expressing both complement and FcRs 
(43–45), we assessed the capture of S-ICs and NS-ICs in the pres-
ence or absence of complement and/or FcRIIB blockade by flow cy-
tometry. As expected, at the highest concentration, both S- and NS-ICs 
were trapped by the noncognate B cells in the presence of complement; 
however, S-ICs bound at higher levels in the presence of complement 
compared with NS-ICs. In contrast, no difference was observed be-
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Fig. 4. Sialylated IgG1 gp120-specific Abs are increased in neutralizers. (A) The radar plot shows the relative differences in gp120-specific IgG1, IgG2, IgG3, and IgG4 
Ab titers in sera from neutralizers (N; red; n = 26) or non-neutralizers (NN; blue; n = 12). (B) The dot plot shows the gp120-specific IgG1 Ab titer differences across the neu-
tralizers and non-neutralizers. (C) The radar plot describes the relative distribution of gp120-specific IgG Ab glycan levels in sera from neutralizers (N; red) or non-neutralizers 
(NN; blue). (D) The dot plot illustrates the percentage of sialylated gp120-specific IgG Abs among the groups. (E) The PLS-DA, using all Fc profile data including gp120-specific 
Ab titers, glycan profiles, binding to FcRs and complement proteins, ADCP, ADCD, and ADCC, was used to separate the two groups. Each dot represents a neutralizer (red) or 
non-neutralizer (blue). (F) The bar graph shows the variable importance in projection (VIP) score rank for the minimal Ab features that were used in the PLS-DA to separate 
the groups. As few as 17 of the total features collected across the cohort were required to nearly completely separate out the neutralizers and non-neutralizers. The varia bles 
were ranked in their importance in driving separation in the model, with the largest bars representing the most important contributions and the smallest bars representing 
more minimal contributions. The direction and color of the bars indicate whether the feature was enriched in the neutralizers (red) or in the non-neutralizers (blue). A Mann-Whitney 
test was used for statistical analysis in (B) and (D). *P < 0.05 and ***P < 0.001. The horizontal bars in all panels indicate mean, and error bars in all panels represent SEM.
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Fig. 5. Sialylated Ab-ICs promote enhanced humoral immune responses. (A) The dot plots show gp120-specific Ab titers (left) or avid Ab titers (right) 10 days after the 
second immunization in BALB/c mice receiving alum alone (green), alum-adjuvanted gp120 (blue), agalactosylated PGT121 (G0-ICs) with alum (aqua), nonsialylated galac-
tosylated PGT121 (G1/G2 NS-ICs) with alum (lavender), or sialylated galactosylated PGT121 (G1/G2 S-ICs) with alum (pink) (n = 3 to 8 mice, two experiments). (B) The dot 
plots highlight the number of fluorescently labeled ICs on noncognate B cells (gp120+ B cells), macrophages (gp120+ SSM), or FDCs (gp120+ FDCs) from draining lymph 
node at 1 and 3 hours after injection with nonsialylated IC (NS-IC) or sialylated IC (S-IC) (n = 4 to 8 mice, two experiments). (C) The confocal microscopy images depict the 
level of IC deposition in a B cell follicle 1 hour after a mouse is immunized with NS-ICs (left) or S-ICs (right) and stained for g120 (blue), macrophages (green), and GL-7 
(red). Representative image of three images from two to three mice per condition. (D) The bar graphs show the number (left) and area occupied (right) of gp120+bead+ 
FDCs in a draining lymph node. (E) The confocal microscopy images depict IC deposition in a B cell follicle 3 hours after immunization and stained with the same targets 
as (C). Representative image of three images from two to three mice per condition. (F and G) The line graphs demonstrate the percentage of bound Raji or naïve human 
B cells after incubation with APC bead–labeled NS-ICs (yellow) or S-ICs (pink), with (colored line) or without complement (gray line), with (blue) or without complement 
(light blue) alone, or -FcRIIB blocking Abs (hatched lines) (F, n = 2; G, n =3). (H) The dot plots show the gp120-specific IgG Ab titers (left) and high-avidity gp120-specific 
Ab titers (right) after immunizing WT or C1q−/− C57BL/6 mice (n = 2 to 8, two experiments) with alum (white), gp120-alum (blue), NS-ICs with alum (yellow), or S-ICs with 
alum (pink). (I) The dot plot highlights the ratio of high-avidity gp120-specific Abs to total gp120-specific Abs in WT (dark pink) versus C1q−/− (light pink) mice after immu-
nization with S-ICs. All ELISAs were performed in triplicate, and a one-way ANOVA followed by Tukey’s post test was used for (A), (B), and (D). Mann-Whitney and one-way 
ANOVA with Holm-Sidak’s multiple comparisons test were used for (H). Two-way ANOVA with Dunnett’s correction comparing samples with the negative control (no Ab, 
no complement) was used for (G). Mann-Whitney test was used in (I). *P < 0.05, **P < 0.01, and ***P < 0.001. The horizontal bars in all panels indicate mean. Error bars 
represent SEM in (B), (D), (H), and (I) and SD in (A).
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Increased binding of S-ICs compared with NS-ICs, in the presence of 
complement, was confirmed on naïve primary human B cells (Fig. 5G). 
These data suggest a dominant role for S-IC interaction with com-
plement in IC capture.
To confirm the interaction between S-ICs and complement, we 
performed IC-based immunizations in complement-deficient mice. 
Wild-type (WT) or C1q-deficient (C1q−/−) congenic mice were im-
munized twice with the ICs or antigen alone. As expected, antigen- 
specific Ab responses were highest in the WT mice immunized with 
S-ICs, with intermediate levels observed in WT mice vaccinated with 
NS-ICs or antigen alone (Fig. 5H). However, a significant reduction 
in Ab titers and avidity were observed in the C1q−/− mice vaccinated 
with S-ICs compared with WT mice (Fig. 5H). Moreover, whereas 
all animals appeared to reach a plateau after the second boost, the 
C1q−/− mice immunized with S-ICs exhibited lower Ab titers and 
avidity compared with WT counterparts (Fig. 5, H and I). These 
data provide further evidence to support a role in Ab sialylation in 
complement-dependent IC delivery for B cell priming and boost-
ing. Although these data do not preclude a role for other FcRs in 
IC-mediated antigen deposition in the lymph node, they support a 
critical role for sialylated Ab-induced complement deposition as a 
driver of high-affinity B cell responses.
DISCUSSION
Although efforts in vaccine design to induce bNAbs continue to 
struggle to drive broad tier 2 heterologous immunity, our evolving 
appreciation for the unique immunological features of the broad 
cross- tier neutralizing breadth that emerges naturally in a select 
population of infected individuals provides unexpected insights for 
the rational development of a protective vaccine. Here, we observed 
that individuals who developed bNAbs had HIV-specific Abs with 
enhanced CR and FcR binding, selectively skewed to induce phago-
cytosis and complement deposition via enhanced HIV-specific Ab 
Fc domain sialylation. Given the importance of Fc binding for antigen 
deposition in the GC and our emerging appreciation for enhanced 
and persistent GC activation among individuals with neutralizing 
Abs (10, 12, 15, 46), we speculated that the enhanced Fc functionality 
could actively contribute to the evolution of HIV-specific neutraliza-
tion breadth. ICs generated with either Abs from individuals with 
these enhanced Fc functions or highly sialylated mAbs induced higher 
titers of more avidly binding Abs after IC immunization. Thus, these 
data suggest that the Fc domain of the Ab may modulate the forma-
tion of the GC reaction, catalyzing the persistent selection and affinity 
maturation of B cells required to drive the unusual B cell selection 
associated with the development of bNAbs against HIV.
Rational vaccine design has led to the creation of both stabilized 
trimers and minimal scaffolds able to focus the immune response to 
sites of neutralization vulnerability (8, 47, 48). However, vaccination 
with these constructs continue to induce Abs with narrow breadth, 
likely due to a limited amount of affinity maturation. This has led 
the field to explore novel immunization strategies and alternate adju-
vants, as well as to focus vaccine design on eliciting bNAbs in the 
absence of high levels of somatic hypermutation (6, 49, 50). Our re-
sults suggest that naturally modified Abs can selectively augment 
affinity maturation via the rapid capture and delivery of antigens to 
the GC. These data are consistent with studies of influenza vaccina-
tion, where the level of HA-specific Ab sialylation was associated with 
the extent of affinity maturation (32). In our study, the administration 
of selectively glycosylated Abs at the time of antigen exposure led to a 
marked increase in antigen deposition and maturation of high-avidity 
Abs, pointing to a role for antigen-specific Ab glycosylation as a regu-
lator of GC activity. Whereas Fab glycosylation is more uniform (41) 
and not involved in Fc/FcR interactions (42), mounting data suggest 
that Ab Fc glycosylation is programmed in an antigen-specific man-
ner (51), modulated by vaccination (51, 52), and tuned by adjuvants 
(53), which offers an opportunity for manipulating the quality of in-
nate immune–recruiting Abs to enhance immunity upon boosting.
Beyond the role of immune activation, low CD4 T cell counts, 
and high viral loads as drivers of neutralizing Ab breadth, recent 
data suggest that individuals who generate bNAbs have autoimmune- 
like transcriptional signatures (54–56). These transcriptional pro-
grams may enable B cells to break the necessary tolerance to evolve 
polyreactive B cell receptors and drive extensive affinity maturation 
(5, 56, 57), even within framework regions that are rarely targeted 
for somatic mutation in healthy B cells (10). Similarly, IC levels and 
signaling have been linked to autoimmune signatures in B cells in 
individuals with rheumatoid arthritis and lupus (58–60). However, 
whether neutralizers have autoimmune-like signatures due to intrinsic 
differences in their B cell populations or due to the higher abundance 
of ICs that can interact with FcRs and CRs is unknown. Nevertheless, 
it is plausible that increased IC signaling could lead not only to en-
hanced antigen deposition but also to increased B cell activation, en-
abling antigen-specific B cells to undergo more extensive maturation, 
tolerate more mutations, and even develop responses to cross-reactive 
epitopes. Thus, linked to emerging rationally designed antigens, im-
munization strategies that also selectively direct the Fc domain of the 
induced humoral immune response may stimulate the needed matu-
ration to induce protective immunity.
Complement has a vital role in IC delivery to FDCs (17, 19, 20); 
however, the specific Ab modifications that enable more effective 
IC capture within GCs has been less clear. A number of different 
cells contribute to the delivery of ICs to the GC including naïve non-
cognate B cells and macrophages, which typically acquire ICs via 
different combinations of FcRs and CRs (35, 61, 62). Previous asso-
ciations between sialylated HA-specific Abs and affinity maturation 
(32) suggested that enhanced IC deposition was linked to IC signaling 
via CD23 (FcRII), which is highly expressed on B cells. Although 
CD23 may have a role in affinity maturation (63), the data presented 
here build on our previous understanding of the critical role of com-
plement in IC capture and deposition on FDCs and provide evidence 
for a mechanistic involvement of sialylation in the acceleration of 
antigen deposition and B cell maturation. Whether the deposited ICs 
accelerate affinity maturation by providing more antigen to drive 
higher frequencies of B cells that must compete more aggressively 
for limited T cell help or lead to tighter binding ICs that require B 
cell receptors to capture antigen more “avidly” for survival signals is 
unclear. It remains unknown whether the antigen specificity of the 
ICs influences this effect. Data from our longitudinal samples indi-
cate that Fc interactions are higher in patients that develop neutraliz-
ing Abs even before neutralizing Abs have developed, suggesting that 
non-neutralizing Abs could contribute to this effect. Future studies 
focusing on human Abs in human Fc chimeric mice, in the presence of 
other mAb specificities, including those that are non-neutralizing, 
linked to sophisticated affinity maturation measures, may elucidate 
the mechanisms underlying the adjuvanting effects of the IC-Fc. None-
theless, the data here highlight the “adjuvanting” activity of sialylated 
Abs in B cell maturation, pointing to potential opportunities to leverage 
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the Fc domain to drive enhanced affinity maturation in the context 
of HIV vaccination.
Complement-activating Abs have also been implicated in the de-
struction of HIV virions (64). Thus, sialylation may provide a bi-
functional advantage in driving enhanced affinity maturation and 
direct antiviral control of HIV. Although HIV can mutate rapidly to 
escape the selection pressure from neutralizing Abs in the context of 
natural infection, it is plausible that vaccines inducing complement- 
depositing Abs against HIV may enhance both Fab- and Fc-mediated 
control of the virus. Thus, with our emerging ability to directly pro-
gram Ab glycosylation, via distinct immunogens (51) or adjuvants 
(53), next-generation vaccine strategies may harness the full antiviral 
breadth of the humoral immune response. Thus, coupled to sophisti-
cated emerging immunogens, manipulation of the Fc domain of the 
Ab may support the evolution of neutralizing Abs that block most 
strains of HIV infection.
MATERIALS AND METHODS
Study design
The goals of this study were to identify unique properties of the Abs 
from individuals with bNAbs to HIV and to determine whether these 
properties could affect the humoral immune response. We used 
systems serology, computational analysis, enzyme-linked immuno-
sorbent assay (ELISA), glycan analysis, Luminex, flow cytometry, 
confocal microscopy, and mouse immunization to accomplish these 
goals. The samples were blinded throughout the initial Fc profiling 
and unblinded for analysis. The number of independent experiments 
and inclusion of individuals is described in the figure legends and in 
Materials and Methods.
Study individuals
A total of 131 controllers were included for cross-sectional studies, 
including both elite controllers, who spontaneously control viral 
replication to undetectable levels (<75 copies/ml; CD4, 353 to 1813 
cells/mm3), and viremic controllers with detectable but low viral loads 
(~20 to 1658 copies of RNA/ml; CD4, 172 to 1794 cells/mm3) (15). 
Days after diagnosis of HIV range from 1 to 30 years, with simi-
lar distributions across neutralizers and non-neutralizers. All indi-
viduals signed informed consent, and the study was approved by the 
Massachusetts General Hospital (MGH) Institutional Review Board. 
HIV-1 neutralization breadth was assessed using the TZM-bL cell–based 
pseudovirus neutralization assay (65) against a panel of Env pseudo-
viruses derived from nine clade B tier 2 (AC10.0.29, RHPA4259.7, 
THRO4156.18, REJO4541.67, WITO4160.33, TRO.11, SC422661.8, 
QH0692.42, and CAAN5342.A2) and two tier 3 (PVO.4 and TRJO4551.58) 
neutralization sensitivities. Neutralization was defined as at least 50% 
inhibition of infection at a 1:20 dilution. The neutralization breadth was 
defined as the percentage of the 11 isolates neutralized by each plasma 
sample; neutralizers were able to neutralize anywhere from 1 virus 
(9% breadth) to all 11 viruses (100% breadth), and non-neutralizers 
had undetectable cross-neutralization against all 11 tier 2/3 viruses. 
All samples that showed reactivity to the murine leukemia virus–
pseudotyped virion controls were excluded.
In addition, longitudinal plasma samples were included from 
26 acutely infected individuals who were recruited as part of the 
San Diego Acute and Early Infectious Disease Research Program (7). 
Twelve individuals developed neutralizing Ab breadth after 2 to 
3 years of infection, whereas 14 individuals (matched for age, gender, 
and ethnicity) did not develop any appreciable tier 2 neutralizing Ab 
breadth. Plasma samples were analyzed at 1 month, 6 months, and 
1 year after the estimated time of infection. These limited time points 
were included not only to ensure that sampling occurred before the 
evolution of neutralizing Ab breadth but also to maintain consist-
ency in comparison for matched durations of infection. All indi-
viduals provided informed consent at their respective institutions.
Functional assays
ADCP assay
The THP-1 phagocytosis assay was performed as previously described 
(66). Briefly, THP-1 cells were purchased from the American Type Cul-
ture Collection and cultured as recommended. Biotinylated rgp120-YU2 
(Immune Technology) was used to saturate the binding sites on 1-m 
fluorescent neutravidin beads (Invitrogen) overnight at 4°C. Excess 
antigen was removed by washing, and then beads were incubated with 
patient Ab samples for 2 hours at 37°C. After opsonization, THP-1 cells 
were added and incubated overnight to allow phagocytosis. Cells were 
then fixed with 4% paraformaldehyde (PFA), and the extent of phago-
cytosis was measured via flow cytometry on a BD LSR II flow cyto-
meter equipped with high-throughput sampler. The data are reported 
as a phagocytic score, which takes into account the proportion of ef-
fector cells that phagocytosed and the degree of phagocytosis [inte-
grated mean fluorescence intensity (MFI): frequency × MFI]. Each Ab 
sample was tested over a range of concentrations (0.1 to 100 g/ml).
ADCC assay
The rapid fluorescent ADCC assay was performed as previously de-
scribed (67). Briefly, CEM-NKr cells were pulsed with rgp120-YU2 
proteins (6 g/ml) and labeled with the intracellular dye carboxyfluo-
rescein diacetate succinimidyl ester (CFSE) and the membrane dye 
PKH26. NK cells were enriched directly from seronegative donor 
whole blood by negative selection using RosetteSep (STEMCELL 
Technologies). Purified IgG was added to the labeled, antigen- 
pulsed CEM-NKr cells before the addition of fresh NK cells. The cells 
were incubated for 4 hours at 37°C and then fixed with 4% PFA. 
The proportion of cells that maintained membrane expression of 
PKH26 but lost CFSE staining (i.e., lysed cells) were quantified via 
flow cytometry.
Ab-dependent complement deposition
ADCD was assessed by the measurement of complement component 
C3b on the surface of target cells. CD4-expressing target cells were 
pulsed with the rgp120-YU2 protein and incubated with serum Abs. 
Freshly isolated HIV-negative donor plasma diluted into veronal buf-
fer with 0.1% gelatin (1:10 dilution) and the cells were incubated for 
20 min at 37°C. The cells then were washed with 15 mM EDTA in 
phosphate-buffered saline (PBS), and complement deposition was de-
tected via flow cytometry after staining for C3b (Cedarlane). Replicates 
using heat-inactivated donor plasma were used as negative controls.
IC uptake by Raji B cells and primary human naïve B cells
Ab-dependent binding to CRs was assessed using CR-expressing 
Raji cells (68) or naïve B cells from fresh peripheral blood mononu-
clear cells (PBMCs). Specifically, biotinylated avitag-gp120-YU2 
(ImmuneTech) was combined with allophycocyanin (APC)–labeled 
streptavidin (Invitrogen) for 2 hours at 37°C. Serial dilutions of 
sialylated PGT121 or nonsialylated PGT121 Abs were added to pre-
pare S-ICs or NS-ICs, respectively. ICs were washed with PBS + 5% 
bovine serum albumin (BSA) and incubated with 5 × 104 Raji B cells 
or 106 human PBMCs per well for 30 min at 37°C with or without fresh-
ly reconstituted guinea pig complement in the presence or absence 
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of anti-FcRII Ab. Cells were stained with a viability dye (eBioscience), 
and Abs against CD3, CD14, and CD19, and then fixed with 100 l 
of 4% PFA before flow cytometry analysis. The percentage of bead+ 
Raji B cells or live+CD3−CD14−CD19+ cells were enumerated across 
different conditions.
Luminex subclass assay, FcR, and complement  
protein binding
A custom Luminex assay was used to quantify the relative concen-
tration of HIV-specific Ab subclass levels, as previously described (69). 
Briefly, microplex carboxylated beads (Luminex) were coupled to the 
indicated proteins via covalent N-hydroxysuccinimide (NHS)–ester 
linkages by combining 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide and NHS (Thermo Scientific) in PBS, as recommended by the 
manufacturer (antigens: gp140-SF162, gp120-YU2, gp41- HXBc2, 
p24-HXBc2, and HA-Brisbane/60/09). The coupled beads [50 l of a 
solution (100 microspheres/l) in 0.1% BSA in PBS] were added to 
each well of a 96-well filter plate (Millipore). The purified IgGs [50 l 
of each sample diluted to IgG (200 g/ml)] were added to five wells 
of the 96-well plate and incubated at 4°C overnight. The beads were 
washed three times with 100 l of PBS–Tween 20, and individual 
IgG isotype detection reagents (bulk IgG, IgG1, IgG2, IgG3, and IgG4) 
conjugated to phycoerythrin (PE) (Southern Biotech) were added 
individually to each of one of the five wells. The 96-well plate was 
incubated with shaking for 2 hours, washed three times, and read on 
a Bio-Plex 200 instrument. Similarly, FcRIIA, FcRIIB, FcRIIIA, 
FcRIIIB, and C1q were biotinylated (Pierce 21331), conjugated to PE 
(Southern Biotech), incubated with coupled beads and purified IgG, 
and analyzed on a Bio-Plex 200 instrument to test the FcR and com-
plement protein binding capacity of HIV-specific Abs, as previously 
described (70).
Glycan analysis
The relative abundance of Ab glycan structures was quantified by 
capillary electrophoresis, as previously described (39). Briefly, antigen- 
specific Abs were purified using gp120-coupled magnetic beads (New 
England Biolabs) and then treated with IdeZ protease (New England 
Biolabs) to collect the Ab Fc portion. N-glycans were removed from 
the Fc domains and labeled with 8-aminopyrene-1,3,6-trisulfonic acid 
(APTS) using the GlycanAssure APTS Kit (Thermo Fisher), as de-
scribed in the manufacturer’s protocol. Labeled glycans were loaded 
onto the 3500 Genetic Analyzer (Thermo Fisher). Peaks of five major 
glycan structures (G0, G1, G2, bisecting, and sialylated) were identi-
fied. The relative abundance of each glycan structure was determined 
by calculating the area under the curve, normalized for equal amounts 
of loaded APTS dye, of each peak divided by the total area of all peaks.
Purification of Ab glycoforms and ICs
PGT121 mAb was used to generate agalactosylated, galactosylated 
nonsialylated, and galactosylated sialylated Abs and then formulated 
with gp120 to prepare G0-ICs, NS-ICs, and S-ICs, respectively. 
Sialylated PGT121 mAb was used to generate Ïnonsialylated and aga-
lactosylated Abs. The Ab was incubated overnight at 37°C with neura-
minidase (Millipore Sigma) or galactosidase S (New England Biolabs) 
to generate nonsialylated or agalactosylated Abs, respectively. Glyco-
profiles of the modified mAbs were confirmed by glycan sequencing 
(fig. S3A) and by Western blot using Sambucus nigra agglutinin 
(SNA)–biotin that binds to sialic acid. Fc glycoform composition with-
out neuraminidase treatment was 13.14% sialylated (G2S1F) and 86.86% 
neutral (G0F, G1F, G1FB, and G2F). Sialylated or galactosylated 
glycoforms were not detected after neuraminidase or galactosidase 
S treatment, respectively. Neuraminidase-treated nonsialylated PGT121 
retained its ability to bind efficiently to gp120 by ELISA (fig. S3B) and 
surface plasmon resonance (fig. S3C), as previously described (71).
IC preparation
To separate the effects of elevated Ab titers from adjuvanting effects of 
unique Fc domains in the neutralizers, we selected polyclonal pools of 
Abs across the neutralizers and non-neutralizers that had equivalent 
titers and avidity. Specifically, gp120-specific binding titers and avidity 
were assessed across the top 10 neutralizers and the bottom 10 neutral-
izers (fig. S1A). Although gp120-specific titers were higher among the 
neutralizers, four individuals were selected from each group that had 
equivalent gp120-specific titers and avidity (encircled in red). Binding 
curves were performed to define the optimal concentration (1:30) of 
plasma to achieve equivalent bead occupancy (fig. S1, B and C).
For the preparation of ICs, biotinylated avitag-gp120-YU2 
(ImmuneTech) was combined with APC-labeled or unlabeled 
streptavidin (Invitrogen) for 2 hours at 37°C. Polyclonal pools of 
neutralizer/ non-neutralizer Abs were added at a ratio of 1:30. For mAb 
experiments, G0-PGT121, S-PGT121, or NS-PGT121 Abs were added 
at a ratio of 1:2 antigen/Ab and incubated for 2 hours at 37°C. All 
ICs were then incubated with 2:1 (antigen + Ab)/alum for 30 min at 
room temperature and finally brought to a final volume of 100 l 
per mouse with PBS. ICs were tested for endotoxin before immuni-
zation using a Limulus Amebocyte Lysate test (Thermo Fisher) ac-
cording to the manufacturer’s instructions and were found to have 
comparable low/undetectable levels of endotoxin in each sample.
Mice and vaccinations
Pathogen-free BALB/c female mice (the Jackson Laboratory) aged 
6 weeks were used in this study. All animal studies were carried out in 
compliance with current regulations of the MGH Center for Com-
parative Medicine at the Ragon Institute animal facility. To measure 
the frequencies of gp120+ immune cells by flow cytometry and to 
detect the B cell follicles by confocal microscopy, mice received one 
intravenous vaccination with fluorescently labeled ICs in PBS. To 
measure the gp120-specific Ab and B cell responses, mice received 
two intramuscular vaccinations with alum-adjuvanted ICs 3 weeks 
apart, and then analysis was performed 10 days after the last immu-
nization. All formulations were adjusted with PBS to bring up to 
100 l per mouse. C1q−/− (72) and WT mice in a C57BL/6 back-
ground were used to assess the role of the C1q complement protein 
after vaccination; these mouse experiments were approved and per-
formed according to the guidelines of the Washington University 
School of Medicine Animal Safety Committee.
Flow cytometry
For the characterization of the innate and the GC B cell responses, 
cell suspensions prepared from spleen, or pairs of draining inguinal 
lymph nodes from each mouse, were stained with blue live/dead 
cell stain (Invitrogen) for 20 min at room temperature and then in-
cubated with Fc block (BD Biosciences) in PBS plus 1% fetal bovine 
serum (HyClone, Thermo Scientific) for 10 min at 4°C. About 107 
splenocytes or 2 × 106 to 3 × 106 lymph node cells were stained for 
30 min at 4°C with the following mAbs: anti-CD19 APC-H7 (BD 
Biosciences), anti-CD3 BV785 (BioLegend), anti-CD38 peridinin- 
chlorophyll-protein complex (PerCP)–C5.5 (BD Biosciences), and 
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anti-CD95 BV510 (BD Horizon). Cells were analyzed on a FACS Fortessa 
(BD Biosciences), and data analyses were performed using FlowJo 
software v9.6 (Tree Star).
Mouse Ab titers and avidity measurement
Titration of gp120-specific serum IgG was performed on individual 
serum samples with ELISA plates (Nunc MaxiSorp, Thermo Scientific) 
coated overnight with gp120-YU2 (250 ng/ml). Plates were blocked 
with 2% BSA in PBS/0.05% Tween 20 for 1 hour at 37°C and then 
washed three times with 0.05% Tween 20 in PBS and incubated for 
2 hours at 37°C with individual mouse sera in twofold serial dilutions. 
Plates were washed, incubated for 1 hour at 37°C with secondary anti- 
mouse total IgG (1:2000; Sigma-Aldrich), and washed, and 3,3ʹ,5,5ʹ- 
tetramethylbenzidine was added for detection. The color reaction 
was measured with a Tecan reader by determining the optical den-
sity at 450 nm (OD450), which was used to plot the graphs. Avidity 
was measured as the titer of high- avidity Abs that were not washed 
away after plate washing with 7 M urea for 15 min before the addi-
tion of the secondary Ab (73). The ratio of gp120-specific high-avidity 
Abs to gp120-specific total Abs was used to compare groups with dif-
ferent gp120-specific total Ab titers.
Confocal microscopy
Spleens were collected from immunized animals at the appropriate 
time points and cut into ~5-mm-thick pieces, immediately submerged 
in optimal cutting temperature (O.C.T.) compound (Tissue-Tek, Sakura), 
snap-frozen using 2-methylbutane (isobutene) and liquid nitrogen, 
and stored in liquid nitrogen until processing. The cryosections (40 m 
thick) were cut along the entire organ to analyze all planes. The cryo-
sections were fixed using ice-cold acetone for 10 min at room tem-
perature and rehydrated in PBS for 5 min. Sections were then blocked 
by Background Sniper (Biocare) and stained using anti-CD35 (IgG- 
purified, BD Pharmingen) or anti–GL-7 (IgM-purified, eBioscience), 
followed by rat anti-IgG Alexa568 (Abcam) or by rat anti-IgM Texas 
Red (Sigma), respectively. Sections were also stained with anti- CD169 
[fluorescein isothiocyanate (FITC), BioLegend]. The antigen APC- 
labeled gp120 used for the immunizations was detected. After wash-
ing three times with PBS, stained tissue sections were sealed using 
Gold Antifade reagent (Invitrogen–Life Technologies) and a coverslip. 
Images were acquired with a Zeiss LSM 510 confocal microscope.
Statistical analysis
PLS-DA defined the relationship between the input as a linear com-
bination of all features among neutralizers or non-neutralizers (33). 
PLS-DA seeks the latent variables, which linearly combine all fea-
tures, that explain the maximum variance between the groups; this 
approach generates a model with the greatest separation among groups 
with the lowest possible mean squared error. Before PLS-DA, the data 
were normalized with mean centering and variance scaling; 10-fold 
cross-validation was performed by iterative random exclusion of sub-
sets of sample data (in groups of 10%) during model calibration, and 
then the excluded data were used to test model predictions. Ultimately, 
each variable identified in the model was weighted for its contribution 
to splitting the groups, aimed at generating a variable importance in 
projection.
Analysis of variance (ANOVA), followed by Tukey’s, Dunnett’s, 
or Bonferroni’s post tests, was performed using GraphPad Prism 
7 software (GraphPad Software) to compare differences between more 
than two groups. A Spearman correlation, followed by Bonferroni 
correction, was used to assess the linear relation between breadth and 
FcR/C1q binding Abs. Mann-Whitney and Student’s t tests were used 
to compare differences between groups using GraphPad Prism 7. 
Spider plots were generated with Microsoft Excel 2011.
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study also highlights the role of the complement pathway in driving humoral immunity.
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